Artigos com autorizações de acesso público - Freddie HamdySaiba mais
Não disponíveis em nenhum local: 25
Rever
Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies
JA Lane, FC Hamdy, RM Martin, EL Turner, DE Neal, JL Donovan
European journal of cancer 46 (17), 3095-3101, 2010
Autorizações: Cancer Research UK
Rever
Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysis
SM Collin, C Metcalfe, L Zuccolo, SJ Lewis, L Chen, A Cox, M Davis, ...
Cancer epidemiology, biomarkers & prevention 18 (9), 2528-2539, 2009
Autorizações: Cancer Research UK
Rever
Population‐based prostate‐specific antigen testing in the UK leads to a stage migration of prostate cancer
AL Moore, P Dimitropoulou, A Lane, PH Powell, DC Greenberg, ...
BJU international 104 (11), 1592-1598, 2009
Autorizações: Cancer Research UK
Rever
Prostate‐specific antigen testing rates remain low in UK general practice: a cross‐sectional study in six English cities
N Williams, LJ Hughes, EL Turner, JL Donovan, FC Hamdy, DE Neal, ...
BJU international 108 (9), 1402-1408, 2011
Autorizações: Cancer Research UK
Rever
Association of diabetes mellitus with prostate cancer: nested case–control study (Prostate testing for cancer and treatment study)
EL Turner, JA Lane, JL Donovan, MJ Davis, C Metcalfe, DE Neal, ...
International journal of cancer 128 (2), 440-446, 2011
Autorizações: Cancer Research UK
Rever
Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer
AA Aitchison, A Veerakumarasivam, M Vias, R Kumar, FC Hamdy, ...
The Prostate 68 (6), 661-674, 2008
Autorizações: Cancer Research UK
Rever
Associations of aspirin, nonsteroidal anti‐inflammatory drug and paracetamol use with PSA‐detected prostate cancer: Findings from a large, population‐based, case–control study …
AS Murad, L Down, G Davey Smith, JL Donovan, J Athene Lane, ...
International journal of cancer 128 (6), 1442-1448, 2011
Autorizações: Cancer Research UK
Rever
Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression
E Ricci, E Mattei, C Dumontet, CL Eaton, F Hamdy, G van der Pluije, ...
The Prostate 73 (16), 1738-1746, 2013
Autorizações: UK Medical Research Council
Rever
Role of active surveillance and focal therapy in low-and intermediate-risk prostate cancers
H van der Poel, L Klotz, G Andriole, AR Azzouzi, A Bjartell, O Cussenot, ...
World journal of urology 33, 907-916, 2015
Autorizações: National Institute for Health Research, UK
Rever
Positron emission tomography and whole-body magnetic resonance imaging for metastasis-directed therapy in hormone-sensitive oligometastatic prostate cancer after primary …
A Farolfi, B Hadaschik, FC Hamdy, K Herrmann, MS Hofman, DG Murphy, ...
European urology oncology 4 (5), 714-730, 2021
Autorizações: US Department of Defense, Medical Research Future Fund, Australia
Rever
Does the introduction of prostate multiparametric magnetic resonance imaging into the active surveillance protocol for localized prostate cancer improve patient re‐classification?
RJ Bryant, B Yang, Y Philippou, K Lam, M Obiakor, J Ayers, V Chiocchia, ...
BJU international 122 (5), 794-800, 2018
Autorizações: Cancer Research UK, National Institute for Health Research, UK
Rever
Survival among men at high risk of disseminated prostate cancer receiving initial locally directed radical treatment or initial androgen deprivation therapy
P Sooriakumaran, T Nyberg, O Akre, A Widmark, F Hamdy, M Graefen, ...
European urology 72 (3), 345-351, 2017
Autorizações: Swedish Research Council, National Institute for Health Research, UK
Rever
Estimating age and ethnic variation in the histological prevalence of prostate cancer to inform the impact of screening policies
J Leal, F Hamdy, J Wolstenholme
International Journal Of Urology 21 (8), 786-792, 2014
Autorizações: Cancer Research UK, National Institute for Health Research, UK
Rever
Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe
K Fizazi, PA Abrahamsson, G Ahlgren, J Bellmunt, D Castellano, S Culine, ...
European urology 67 (5), 904-912, 2015
Autorizações: Cancer Research UK, National Institute for Health Research, UK
Rever
Prostate cancer cells home to bone using a novel in vivo model: Modulation by the integrin antagonist GLPG0187
KJ Reeves, JE Hurrell, M Cecchini, G van der Pluijm, JM Down, CL Eaton, ...
International journal of cancer 136 (7), 1731-1740, 2015
Autorizações: Cancer Research UK
Rever
The impact of reducing the prostate‐specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate‐cancer detection programme
AW Roddam, FC Hamdy, NE Allen, CP Price, ...
BJU international 100 (3), 514-517, 2007
Autorizações: Cancer Research UK
Rever
Gleason drift in the NIHR P rotec T study
J Oxley, A Simpkin, J Goepel, M Varma, D Griffiths, K Grigor, N Mayer, ...
Histopathology 66 (3), 438-446, 2015
Autorizações: UK Medical Research Council, National Institute for Health Research, UK
Rever
Prostatic capsular incision during radical prostatectomy has important oncological implications: a systematic review and meta‐analysis
Y Philippou, E Harriss, L Davies, I Jubber, T Leslie, RW Bell, RJ Bryant, ...
BJU international 124 (4), 554-566, 2019
Autorizações: Cancer Research UK
Rever
Longitudinal prostate-specific antigen reference ranges: choosing the underlying model of age-related changes
AJ Simpkin, C Metcalfe, RM Martin, JA Lane, JL Donovan, FC Hamdy, ...
Statistical methods in medical research 25 (5), 1875-1891, 2016
Autorizações: Cancer Research UK, UK Medical Research Council, National Institute for …
Rever
Clinical performance of magnetic resonance imaging and biomarkers for prostate cancer diagnosis in men at high genetic risk
O Cussenot, R Renard‐Penna, S Montagne, V Ondet, A Pilon, J Guechot, ...
Bju International 131 (6), 745-754, 2023
Autorizações: Cancer Research UK
As informações de publicação e financiamento são determinadas automaticamente por um programa informático.